

1	2	3	4	5	6	7
Lower risk/ potential reward Not risk-free					Higher risk/ potential reward	

JPMorgan Funds -

# Global Healthcare Fund

Class: JPM Global Healthcare A (dist) - GBP

## Fund overview

ISIN LU0432979531	Sedol B54YX47	Bloomberg JPHLUAG LX	Reuters LU0432979531.LUF
<b>Investment objective:</b> To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.			
<b>Investment approach</b> <ul style="list-style-type: none"><li>• Uses a fundamental, bottom-up stock selection process.</li><li>• Investment process built on stock level analysis by a global research team.</li><li>• Targets innovative and attractively valued companies using strong scientific rationale as the basis for all investment decisions.</li></ul>			
<b>Portfolio manager(s)</b> Anne Marden Matthew Cohen Holly Fleiss	<b>Share class currency</b> GBP <b>Fund assets</b> USD 4865.9m <b>NAV GBP</b> 386.89	<b>Class launch</b> 16 Oct 2009 <b>Domicile</b> Luxembourg <b>Entry/exit charges</b> Entry charge (max) 5.00% Exit charge (max) 0.50% <b>Ongoing charge</b> 1.81%	
<b>Investment specialist(s)</b> Frances Gerhold	<b>Fund launch</b> 2 Oct 2009		
<b>Fund reference currency</b> USD			
<b>ESG information</b> <b>ESG approach - ESG Promote</b> Promotes Environmental and / or social characteristics. <b>SFDR classification: Article 8</b> "Article 8" strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective.			


## Fund ratings As at 31 July 2022

Overall Morningstar Rating **★★★★**Morningstar Category **™ Sector Equity Healthcare**

## Performance

**1** Class: JPM Global Healthcare A (dist) - GBP**2** Benchmark: MSCI World Healthcare Index (Total Return Net)

### Growth of GBP 100,000 Calendar years



### Quarterly rolling 12-month performance (%)

As at end of June 2022

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022
<b>1</b>	6.50	11.06	20.15	12.35	3.05
<b>2</b>	3.19	14.98	17.28	10.05	11.19

### Calendar Year Performance (%)

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>1</b>	16.81	58.15	29.74	7.35	0.98	9.91	8.16	17.46	19.42	12.18
<b>2</b>	12.39	33.75	25.45	12.77	11.17	9.43	8.88	18.49	10.01	20.91

### Return (%)

	Cumulative			Annualised		
	1 month	3 months	1 year	3 years	5 years	10 years
<b>1</b>	4.81	3.88	7.64	12.13	11.42	15.49
<b>2</b>	3.06	3.67	11.18	12.90	12.22	15.29

### Performance Disclosures

**Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.**

### ESG

For more information on environmental, social and governance (ESG) integration and our approach to sustainable investing at J.P. Morgan Asset Management please visit <https://am.jpmorgan.com/lu/esg>

## Dividend History

Amount	Record Date	Payment Date	Annualised yield
£0.0100	11 Sep 2017	28 Sep 2017	0.00 %
£0.0100	04 Sep 2018	19 Sep 2018	0.00 %
£0.0100	04 Sep 2019	19 Sep 2019	0.00 %
£0.0100	09 Sep 2020	24 Sep 2020	0.00 %
£0.0100	08 Sep 2021	27 Sep 2021	0.00 %


## Portfolio analysis

Measurement	3 years	5 years
Correlation	0.93	0.93
Alpha (%)	-0.68	-0.71
Beta	1.13	1.12
Annualised volatility (%)	14.89	14.45
Sharpe ratio	0.83	0.80
Tracking error (%)	5.84	5.45
Information ratio	-0.06	-0.07

## Holdings

Top 10	Sector	% of assets
UnitedHealth	Healthcare Services	9.1
AbbVie	Biotechnology	5.2
Eli Lilly	Pharmaceutical	5.0
Thermo Fisher Scientific	Medtech	4.8
AstraZeneca	Pharmaceutical	4.0
Bristol-Myers Squibb	Pharmaceutical	3.6
Novo Nordisk	Pharmaceutical	3.4
Centene	Healthcare Services	2.9
Johnson & Johnson	Pharmaceutical	2.6
Amgen	Biotechnology	2.5

## Market cap (%) (USD)



Regions (%)	Compared to benchmark
North America	77.9 +4.9
Europe & Middle East ex UK	10.7 -5.7
United Kingdom	6.0 +1.7
Japan	1.6 -2.8
Emerging Markets	0.6 +0.6
Pacific ex-Japan	0.0 -1.9
Cash	3.2 +3.2

Sectors (%)	Compared to benchmark
Pharmaceutical	30.1 -10.2
Biotechnology	25.5 +11.7
Healthcare Services	21.3 +2.4
Medtech	19.9 -7.1
Cash	3.2 +3.2

## Key risks

The Sub-Fund is subject to **Investment risks** and **Other associated risks** from the techniques and securities it uses to seek to achieve its objective.

The table on the right explains how these risks relate to each other and the **Outcomes to the Shareholder** that could affect an investment in the Sub-Fund.

Investors should also read [Risk Descriptions](#) in the Prospectus for a full description of each risk.

### Investment risks *Risks from the Sub-Fund's techniques and securities*

Techniques	Securities	
Concentration	Equities	Smaller companies
Hedging		

### Other associated risks *Further risks the Sub-Fund is exposed to from its use of the techniques and securities above*

Currency	Liquidity	Market
----------	-----------	--------

### Outcomes to the Shareholder *Potential impact of the risks above*

Loss	Volatility	Failure to meet the Sub-Fund's objective.
Shareholders could lose some or all of their money.	Shares of the Sub-Fund will fluctuate in value.	

## General Disclosures

Before investing, obtain and review the current prospectus, Key Investor Information Document (KIID) and any applicable local offering document. These documents, as well as the annual and semi-annual reports and the articles of incorporation, are available in English free from your financial adviser, your J.P. Morgan Asset Management regional contact, the fund's issuer (see below) or at [www.jpmm.lu](http://www.jpmm.lu). A summary of investor rights is available in English at <https://am.jpmorgan.com/lu/investor-rights>. J.P. Morgan Asset Management may decide to terminate the arrangements made for the marketing of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date. No provider of information presented here, including index and ratings information, is liable for damages or losses of any type arising from use of their information. No warranty of accuracy is given and no liability in respect of any error or omission is accepted.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy [www.jpmm.com/emea-privacy-policy](http://www.jpmm.com/emea-privacy-policy)

For additional information on the sub-fund's target market please refer to the Prospectus.

**Synthetic risk and reward indicator** Based on share class volatility for the past 5 years. See Key Investor Information Document (KIID) for details.

## Performance information

Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees.

The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation.

Indices do not include fees or operating expenses and you cannot invest in them.

The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

Dividend income shown is gross of any applicable tax.

## Holdings information

Market Cap excludes cash.

## Information Sources

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

**All data is as at the document date unless indicated otherwise.**

© 2022 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

## Regional Contact

JPMorgan Asset Management (UK) Limited Registered address: 25 Bank Street, Canary Wharf, London E14 5JP, United Kingdom. Authorised and regulated by the Financial Conduct Authority. Registered in England No. 01161446.

## Issuer

JPMorgan Asset Management (Europe) S.à r.l., 6, route de Trèves, L-2633 Senningerberg, Luxembourg. B27900, corporate capital EUR 10.000.000.

## Definitions

**NAV** Net Asset Value of a fund's assets less its liabilities per Share.

**Overall Morningstar Rating™** assessment of a fund's past performance, based on both return and risk and shows how similar investments compare with their competitors. Investment decisions should not be based on a high rating alone.

**Correlation** measures the relationship between the movement of the fund and its benchmark. A correlation of 1.00 indicates that the fund perfectly matched its benchmark.

**Alpha (%)** a measure of excess return generated by a manager compared to the benchmark. An alpha of 1.00 indicates that a fund has outperformed its benchmark by 1%.

**Beta** a measure of a fund's sensitivity to market movements (as represented by the fund's benchmark). A beta of 1.10 suggests the fund could perform 10% better than the benchmark in up markets and 10% worse in down markets, assuming all other factors remain constant.

**Annualised volatility (%)** an absolute measure of volatility and measures the extent to which returns vary up and down over a given period. High volatility means that the returns have been more variable over time. The measure is expressed as an annualised value.

**Sharpe ratio** measures the performance of an investment adjusting for the amount of risk taken (compared a risk-free investment). The higher the Sharpe ratio the better the returns compared to the risk taken.

**Tracking error (%)** measures how much a fund's returns deviate from those of the benchmark. The lower the number the closer the fund's historic performance has followed its benchmark.

**Information ratio (IR)** measures if a manager is outperforming or underperforming the benchmark and accounts for the risk taken to achieve the returns. A manager who outperforms a benchmark by 2% p.a. will have a higher IR than a manager with the same outperformance but who takes more risk.